| Pair Name | Resveratrol, Cisplatin | ||
| Phytochemical Name | Resveratrol (PubChem CID: 445154 ) | ||
| Anticancer drug Name | Cisplatin (PubChem CID: 5702198 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Drug Name | Cisplatin |
| Adverse Reactions | Myelosuppression, dry mouth and throat, fever, dry stools. This was inferred hot nature anticancer drug. |
| Recommendations | Cold: Anemarrhena asphodeloides; Urena lobataL; Artemisia scoparia; Swertia mussotii; Swertia pseudochinensis; Gentiana manshurica; Gossampinus malabarica; Pyrrosia sheareri; Pyrrosia sheareri; Iris domestica; Gentiana scabra; Pyrrosia sheareri; Pyrrosia petiolosa |
| Reference | ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899. ref_link |
| Pair Name | Resveratrol, Cisplatin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
| Gene Regulation | Up-regulation | Expression | CDKN1A | hsa1026 |
| Up-regulation | Expression | CDKN2A | hsa1029 | |
| Down-regulation | Expression | IL1B | hsa3553 | |
| Down-regulation | Expression | IL6 | hsa3569 | |
| Up-regulation | Expression | MAPK14 | hsa1432 | |
| Down-regulation | Expression | MMP2 | hsa4313 | |
| Down-regulation | Expression | TNF | hsa7124 | |
| Up-regulation | Expression | TP53 | hsa7157 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| Result | Combination therapy of cisplatin and resveratrol to induce cellular aging in gastric cancer cells: Focusing on oxidative stress, and cell cycle arrest | |||
| Pair Name | Resveratrol, Cisplatin | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Activity | CASP3 | hsa836 |
| Up-regulation | Activity | CASP9 | hsa842 | |
| In Vitro Model | MDA-MB-231 | Breast adenocarcinoma | Homo sapiens (Human) | CVCL_0062 |
| Result | RSV, an effective anti-oxidant, and CDDP as an effective drug in cancer treatment, were found to increase apoptosis when given in the MDA-MB-231 cell. | |||
| Pair Name | Resveratrol, Cisplatin | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Up-regulation | Activity | ATF4 | hsa468 |
| Up-regulation | Expression | BAX | hsa581 | |
| Down-regulation | Expression | BCL2 | hsa596 | |
| Up-regulation | Cleavage | CASP12 | hsa100506742 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Expression | CDC25C | hsa995 | |
| Up-regulation | Phosphorylation | CDK1 | hsa983 | |
| Up-regulation | Activity | CDKN1A | hsa1026 | |
| Up-regulation | Activity | CDKN1B | hsa1027 | |
| Up-regulation | Expression | DDIT3 | hsa1649 | |
| Up-regulation | Expression | EIF2AK3 | hsa9451 | |
| Up-regulation | Phosphorylation | EIF2S1 | hsa1965 | |
| Up-regulation | Expression | HSPA5 | hsa3309 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | AGS | Gastric adenocarcinoma | Homo sapiens (Human) | CVCL_0139 |
| Result | These results indicated that RES is a promising adjuvant for DDP during GC chemotherapy. | |||
| Pair Name | Resveratrol, Cisplatin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in S phase | |||
| Gene Regulation | Up-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | CASP9 | hsa842 | |
| Down-regulation | Expression | CCNA2 | hsa890 | |
| Down-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Phosphorylation | MAPK14 | hsa1432 | |
| Up-regulation | Phosphorylation | MAPK8 | hsa5599 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | SK-OV-3 | Ovarian serous cystadenocarcinoma | Homo sapiens (Human) | CVCL_0532 |
| Result | Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT | |||
| No. | Title | Href |
|---|---|---|
| 1 | Combination therapy of cisplatin and resveratrol to induce cellular aging in gastric cancer cells: Focusing on oxidative stress, and cell cycle arrest. Front Pharmacol. 2023;13:1068863. Published 2023 Jan 4. doi:10.3389/fphar.2022.1068863. | Click |
| 2 | Resveratrol increases the sensitivity of breast cancer MDA-MB-231 cell line to cisplatin by regulating intrinsic apoptosis. Iran J Basic Med Sci. 2021 Jan;24(1):66-72. doi: 10.22038/ijbms.2020.50485.11501. | Click |
| 3 | Resveratrol synergizes with cisplatin in antineoplastic effects against AGS gastric cancer cells by inducing endoplasmic reticulum stress‑mediated apoptosis and G2/M phase arrest. Oncol Rep. 2020 Oct;44(4):1605-1615. doi: 10.3892/or.2020.7708. | Click |
| 4 | Resveratrol Enhances Cytotoxic Effects of Cisplatin by Inducing Cell Cycle Arrest and Apoptosis in Ovarian Adenocarcinoma SKOV-3 Cells through Activating the p38 MAPK and Suppressing AKT. Pharmaceuticals (Basel). 2023 May 17;16(5):755. doi: 10.3390/ph16050755. | Click |
